Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC PILO versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC PILO versus TRASICOR.
BETOPTIC PILO vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betoptic Pilo is a combination of betaxolol (a cardioselective beta-1 adrenergic receptor antagonist) and pilocarpine (a muscarinic cholinergic agonist). Betaxolol reduces aqueous humor production by blocking beta-adrenergic receptors in the ciliary epithelium. Pilocarpine increases aqueous humor outflow by contracting the ciliary muscle and opening the trabecular meshwork.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
One drop of 0.5% betaxolol and 4% pilocarpine combination ophthalmic solution instilled into the affected eye(s) twice daily.
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
Betaxolol: 16–22 hours (clinical context: allows once-daily dosing for glaucoma). Pilocarpine: 0.5–1.5 hours (rapid elimination, requiring multiple daily dosing).
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Betoptic Pilo (betaxolol and pilocarpine) undergoes both renal and hepatic elimination. Betaxolol is primarily metabolized in the liver (active metabolites) with less than 15% excreted unchanged in urine. Pilocarpine is hydrolyzed in plasma and tissues; its metabolites and a small fraction of unchanged drug are excreted renally. Fecal excretion is negligible.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category C
Category C
Beta-Blocker
Beta-Blocker